Stephens Has Lowered Expectations for Delcath Systems (NASDAQ:DCTH) Stock Price

Delcath Systems (NASDAQ:DCTH) had its target price lowered by equities researchers at Stephens from $25.00 to $18.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Stephens’ price target would indicate a potential upside of 107.23% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Delcath Systems in a report on Wednesday, October 8th. HC Wainwright set a $30.00 target price on Delcath Systems and gave the stock a “buy” rating in a report on Monday, October 20th. BTIG Research restated a “buy” rating and set a $23.00 target price on shares of Delcath Systems in a report on Tuesday. Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a report on Tuesday, October 21st. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.40.

Delcath Systems Price Performance

Shares of DCTH stock traded down $0.39 during trading hours on Wednesday, hitting $8.69. 208,156 shares of the company’s stock were exchanged, compared to its average volume of 642,097. The stock’s 50-day moving average is $10.88 and its 200-day moving average is $12.33. The stock has a market cap of $303.84 million, a price-to-earnings ratio of 174.38 and a beta of 0.84. Delcath Systems has a 52 week low of $8.70 and a 52 week high of $18.23.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.02 EPS for the quarter, hitting analysts’ consensus estimates of $0.02. The firm had revenue of $20.56 million during the quarter, compared to analyst estimates of $23.22 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. Equities research analysts forecast that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. USA Financial Formulas acquired a new position in shares of Delcath Systems during the 2nd quarter worth approximately $25,000. California State Teachers Retirement System acquired a new position in shares of Delcath Systems during the 2nd quarter worth approximately $26,000. Tower Research Capital LLC TRC acquired a new position in shares of Delcath Systems during the 2nd quarter worth approximately $40,000. Ameritas Investment Partners Inc. acquired a new position in shares of Delcath Systems during the 2nd quarter worth approximately $42,000. Finally, Legal & General Group Plc acquired a new position in shares of Delcath Systems during the 2nd quarter worth approximately $46,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.